| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Proteasome activator complex subunit 1, 11S regulator complex subunit alpha, REG-alpha, Activator of multicatalytic protease subunit 1, Interferon gamma up-regulated I-5111 protein, IGUP I-5111, Proteasome activator 28 subunit alpha, PA28a, PA28alpha, PSME1, IFI5111 |
| Entrez GeneID | 5720 |
| WB Predicted band size | 28.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PSME1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 220-249 amino acids from the C-terminal region of human PSME1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇涉及PSME1抗体的代表性文献及其摘要概括：
1. **文献名称**：Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
**作者**：Zhang Z, et al.
**摘要**：该研究利用PSME1(PA28α)特异性抗体，通过免疫共沉淀和Western blot技术，揭示了PA28α在p53-MDM2调控通路中的作用，证明其通过促进p53泛素化降解影响肿瘤细胞增殖。
2. **文献名称**：Immunoproteasome assembly is regulated by PA28αβ and PSME1 in autoimmune diseases
**作者**：Chen X, et al.
**摘要**：研究通过免疫荧光和抗体阻断实验，发现PSME1抗体可特异性抑制PA28α的活性，从而调控免疫蛋白酶体组装，为类风湿性关节炎等自身免疫疾病的治疗提供潜在靶点。
3. **文献名称**：PSME1 expression correlates with poor prognosis in hepatocellular carcinoma
**作者**：Wang L, et al.
**摘要**：利用PSME1抗体进行组织芯片免疫组化分析，发现肝癌组织中PSME1高表达与患者生存期缩短显著相关，提示其可作为预后生物标志物。
注：以上文献信息为示例性质，实际引用需根据具体研究年份及数据库检索结果调整。建议通过PubMed等平台以“PSME1 antibody”为关键词获取最新文献。
The PSME1 (Proteasome Activator Subunit 1) antibody targets a key regulatory component of the 20S proteasome, a multi-subunit complex responsible for degrading damaged or misfolded proteins via the ubiquitin-independent pathway. PSME1. also known as PA28α, forms part of the PA28 (11S) proteasome activator complex, which enhances proteolytic activity by binding to the proteasome and facilitating substrate entry. This complex is critical in regulating immune responses, particularly in MHC class I antigen presentation, where it processes intracellular antigens for immune surveillance.
PSME1 is predominantly expressed in immune tissues and is induced by interferon-gamma, linking it to inflammatory and autoimmune conditions. Dysregulation of PSME1 has been implicated in cancers, neurodegenerative diseases, and autoimmune disorders, as altered proteasome activity can disrupt protein homeostasis and immune signaling. Antibodies against PSME1 are widely used in research to study its expression, localization, and interaction partners via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They also aid in exploring its role in disease mechanisms, such as tumor progression or neuroinflammation, and in evaluating potential therapeutic strategies targeting proteasome regulation. Commercial PSME1 antibodies are typically validated for specificity across human, mouse, and rat models, supporting cross-species translational studies.
×
